Takeda overhauls management under Weber's leadership
This article was originally published in Scrip
New senior management changes at Takeda bear the globalizing hallmark of Christophe Weber, who became chief operating officer in April and president in June, and who is expected to take the helm as CEO in the not too distant future. On 16 September Takeda announced a major organizational overhaul, establishing five regional business units, separating the Japan pharma business from the North Asian unit, and merging North Asian into Emerging Market. The goal is "to establish an operation system meeting patients' and medical professionals' needs."
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.